Mylan NV has received a request for information from the Federal Trade Commission in order to launch a preliminary investigation over whether the company violated antitrust laws over its pricing of the EpiPen, a popular allergy drug, according to a report by Bloomberg.
Category: Dey
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and…
… pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com largest and fully-integrated, innovation-led biopharmaceutical …
Mylan announces U.S. launch of generic Concerta Tablets
… than 240 ANDAs pending FDA approval representing approximately $95.6 billion in annual brand sales, according to IMS Health. Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $32.5 billion in annual brand …